Human IFABP/FABP2 (Intestinal Fatty Acid Binding Protein) CLIA Kit
The Human IFABP (FABP2) Intestinal Fatty Acid Binding Protein CLIA Kit offered by Assay Genie is a cutting-edge assay designed for the precise measurement of IFABP levels in human serum, plasma, and cell culture supernatants. This kit provides exceptional sensitivity and specificity, ensuring accurate and consistent results for a variety of research applications.IFABP, also known as FABP2, is a key protein involved in fatty acid transport and metabolism in the intestine. Dysregulation of IFABP has been linked to various gastrointestinal disorders, making it a valuable biomarker for studying and understanding these conditions.
The IFABP CLIA Kit enables researchers to investigate the role of IFABP in disease pathogenesis and explore potential therapeutic interventions.Don't miss out on this advanced tool for studying intestinal fatty acid binding protein - order your Human IFABP (FABP2) Intestinal Fatty Acid Binding Protein CLIA Kit from Assay Genie today!
Product Name:
Human IFABP/FABP2 (Intestinal Fatty Acid Binding Protein) CLIA Kit
SKU:
HUES00139
Target:
Human IFABP/FABP2 (Intestinal Fatty Acid Binding Protein)
Size:
96T
Assay type:
Sandwich-CLIA
Assay time:
3.5h
Sensitivity:
18.75 pg/mL
Detection range:
31.25-2000 pg/mL
Kit component:
Component
Quantity (24 Assays)
Quantity (96 Assays)
Storage
CLIA Plate
8 wells x 3 strips
8 wells x 12 strips
-20°C, 6 months
Reference Standard
1 vial
2 vials
Concentrated Biotinylated Detection Ab (100×)
1 vial, 60 µL
1 vial, 120 µL
Concentrated HRP Conjugate (100×)
1 vial, 60 µL
1 vial, 120 µL
-20°C (shading light), 6 months
Reference Standard & Sample Diluent
1 vial, 20 mL
1 vial, 20 mL
4°C, 6 months
Biotinylated Detection Ab Diluent
1 vial, 14 mL
1 vial, 14 mL
HRP Conjugate Diluent
1 vial, 14 mL
1 vial, 14 mL
Concentrated Wash Buffer (25×)
1 vial, 30 mL
1 vial, 30 mL
Substrate Reagent A
1 vial, 5 mL
1 vial, 5 mL
4°C (shading light)
Substrate Reagent B
1 vial, 5 mL
1 vial, 5 mL
Desiccant
1
1
Plate Sealer
5 pieces
5 pieces
Product Description
1 copy
1 copy
This CLIA kit uses the Sandwich-CLIA principle. The micro CLIA plate provided in this kit has been pre-coated with an antibody specific to Human IFABP. Standards or samples are added to the micro CLIA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human IFABP and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human IFABP, biotinylated detection antibody and Avidin-HRP conjugate will appear fluorescence. The Relative light unit (RLU) value is measured by the Chemiluminescence immunoassay analyzer. The RLU value is positively associated with the concentration of Human IFABP. You can calculate the concentration of Human IFABP in the samples by comparing the RLU value of the samples to the standard curve.
Linearity:
Serum (n=5)
EDTA plasma (n=5)
Cell culture media (n=5)
1:2
Range (%)
96-111
97-110
90-104
Average (%)
102
104
97
1:4
Range (%)
101-119
88-103
90-104
Average (%)
109
95
96
1:8
Range (%)
98-113
92-105
92-107
Average (%)
106
97
99
1:16
Range (%)
86-100
94-105
92-108
Average (%)
93
99
100
Recovery:
Sample Type
Range (%)
Average Recovery (%)
Serum (n=5)
89-103
94
EDTA plasma (n=5)
97-114
104
Cell culture media (n=5)
99-113
104
Precision:
Intra-assay Precision
Inter-assay Precision
Sample
1
2
3
1
2
3
n
20.0
20.0
20.0
20.0
20.0
20.0
Mean (ng/mL)
109.71
245.91
875.57
116.29
236.29
822.75
Standard deviation
9.24
26.78
55.16
11.82
19.61
83.84
C V (%)
8.42
10.89
6.3
10.16
8.3
10.19
Sample type &Sample volume:
serum, plasma and other biological fluids; 100μL
Reproducibility:
Both intra-CV and inter-CV are < 15%.
Application:
This CLIA kit applies to the in vitro quantitative determination of Human IFABP concentrations in serum, plasma and other biological fluids.
Specificity:
This kit recognizes Human IFABP in samples. No significant cross-reactivity or interference between Human IFABP and analogues was observed.
